A Small Texas Think Tank Cultivated Covid Dissidents. Now They’re Running US Health Policy.

Martin Kulldorff, chair of the Trump administration’s reconstituted CDC vaccine panel, made a shocking — and misleading — statement as the group met in September. Referring to a clinical trial, Kulldorff, a biostatistician and former professor at Harvard Medical School, said eight babies born to women who received Pfizer’s covid vaccine while pregnant had birth…

Read More

With FDA Approval for RNAi Drug, Arrowhead Pharma Starts Price War With Rival Ionis

Arrowhead Pharmaceuticals’ RNAi drug plozasiran, brand name Redemplo, is now the second FDA-approved therapy for familial chylomicronemia syndrome, an inherited lipid disorder. Beyond its claims of safety and dosing advantages, Arrowhead set a dramatically lower price for its first commercial product, which will compete against an Ionis Pharmaceuticals drug. The post With FDA Approval for…

Read More

Struggling UnitedHealth Group is a Huge Smoking Black Box

By JEFF GOLDSMITH In mid-April 2025, UnitedHealth Group (UNH) reported its 1Q25 operating results, including a modest shortfall in expected earnings and lowered its 2025 earnings forecast by 12%. The company blamed accelerating medical costs and federal policy changes for their most profitable service line, Medicare Advantage. Market reaction was swift and savage. UNH stock…

Read More